Teens take on 10k challenge after health struggles
The group are preparing to complete the 10km (6.2 mile) race on Sunday with the support of staff from the Royal Manchester Children's Hospital.
Among them are Issie and Ayyub, who were admitted to hospital last year due to rare illnesses.
The charity challenge will mark an important milestone in their recovery.
In February 2024, Issie, 15, was admitted to hospital with a brain haemorrhage.
"It caused me to be in ICU for a month and I've had three brain surgeries," she said.
"When I was on ICU they didn't think I would be able to walk."
Issie was recently discharged but continues to undergo intense rehab as an outpatient to relearn how to walk.
"I can't walk the whole 10km because of fatigue but I am going to do the last 1km on my own," said the 15-year-old.
Ayyub, 16, who is an inpatient, was admitted to hospital in March 2024 with acute flaccid myelitis, a rare condition that affects the spinal cord.
"I developed like a little bit of a cold, which ended up leaving me paralysed," he said.
"The cold I had ended up attacking my whole spinal cord, leaving me in ICU for three months.
"Doctors said that I was going to be ventilated for the rest of my life, but I ended up getting my breathing back so I've become a lot stronger since then. It's a life-changing experience."
Ayyub is hoping to self-propel his wheelchair across the Great Manchester Run finish line.
Emily Davies, a specialist paediatric physio at the hospital, said: "All of our patients are incredibly inspiring and incredibly resilient brave people and I definitely feel inspired by my patients."
The team are raising money for the hospital's youth service, which they all used during their time as patients.
Molly Bradley, a youth worker at the hospital, said: "What we're providing is someone to speak to, a safe adult they can talk to about all the difficulties that come with being in a hospital.
"Being a teenager is tough at any time of their life, but being a teenager in hospital and not getting to go and see your friends and do everything that everyone else is doing can be really upsetting for young people."
Ayyub said: "The money for the trust will be the best thing because the youth service has helped a lot with my mental health in general."
Issie said this was a cause close to heart as "the money will go to help other young people".
Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230.
https://www.bbc.co.uk/mediacentre/2025/great-manchester-run-great-north-run
https://mft.nhs.uk/rmch/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
8 minutes ago
- Medscape
Safety Watchdog Flags Ongoing Maternity Risks
The Health Services Safety Investigations Body (HSSIB) has released a preliminary report on maternity and neonatal safety in England. The exploratory review, carried out in spring 2025, highlighted concerns across the entire maternity and neonatal care pathway despite years of initiatives aimed at improvement. The review comes after a series of high-profile scandals, including at Shrewsbury and Telford Hospital NHS Trust and Nottingham University Hospitals NHS Trust. The Shrewsbury inquiry, led by senior midwife Donna Ockenden, found that approximately 201 babies and nine mothers might have survived if they had received better care. The Nottingham review — also led by Ockenden — remains ongoing. Safety Concerns and Baby Deaths The HSSIB's latest report indicates that safety concerns persist. Between October 2023 and June 2025, the board received 35 reports of safety concerns in maternity or neonatal services. These accounted for about 10% of all safety concerns received during that period. All cases involved "very serious harm", including 10 baby deaths. Sixteen incidents occurred during labour, and 12 during the neonatal period. Most reports came from women or family members, although some were submitted by healthcare staff. Full Investigation Paused The board had begun a scoping exercise to assess the need for a full investigation. However, the work was paused in June after the Secretary of State for Health and Social Care announced a national investigation into maternity and neonatal services, due to report in December 2025. Health Secretary Wes Streeting said that multiple reviews into local trusts had found "similar failings in compassionate care" after maternity service failures "that should never have happened". He acknowledged "systemic" failings dating back more than 15 years and said families had been "gaslit" in their search for answers about their babies' deaths. Although pausing its work, the HSSIB published its exploratory findings to support the national investigation. These were based on the 35 recent safety reports, meetings with 17 stakeholders, and a 2021 report by its precursor organisation, the Healthcare Safety Investigation Branch. 'Compounded Harms' to Families The report identified 11 key themes. Progress had been made in maternity and neonatal outcomes, staffing levels, and governance, but disparities in care and outcomes persisted, partly due to health inequalities. The HSSIB found that maternity and neonatal systems were overly complex, with inconsistent collaboration and poor information sharing. Local governance often operated in isolation, and services struggled to identify and respond to clinical risks or to learn from the harms that happened to women and babies during pregnancy, labour, and birth. "Patients experience compounded harm due to issues within the wider healthcare system," the report concluded. It highlighted that local investigations, complaints processes, and legal proceedings such as inquests often caused additional harm. "Staff and trusts can lose sight of compassion during this process," it said. Four Areas for Further Review The HSSIB recommended four areas for potential further investigation: National structures responsible for providing direction and oversight for maternity services. Local governance and its relationship to national bodies. Standards and approaches of local investigations when things go wrong. Education, training, and professional standards for clinicians. Staff Experience Cumulative Stress The report said that maternity and neonatal staff also experienced cumulative stress and harm. It raised concerns about the standards set in undergraduate and postgraduate education, and whether these could be met in practice, noting that too many recommendations were being made, with limited implementation. The HSSIB warned that multiple, high-profile maternity investigations and inquiries had eroded public confidence in maternity services. Some women were avoiding hospitals that had been the focus of national investigations, undermining recruitment and damaging staff morale. The report cited instances of midwives receiving death threats or being berated for working in 'failing' services. Stakeholders had told the HSSIB that clinicians had also become more risk-averse for fear of blame, a defensive approach that "drives the behaviour that compounds the harm women and families experience".
Medscape
4 hours ago
- Medscape
Vitamin D Deficiency Tied to Cataract Risk in Young Adults
TOPLINE: Severe deficiency of vitamin D (< 25 nmol/L) has been associated with a significantly increased risk for cataracts, particularly in people younger than 50 years. METHODOLOGY: Researchers examined cross-sectional and longitudinal associations between serum levels of 25-hydroxyvitamin D and the risk for cataracts, using data from the UK Biobank. The cross-sectional analysis included 442,255 participants with data on serum levels of vitamin D; among them, 427,923 participants (mean age, 56.2 years; 53.6% women) without cataracts at baseline were followed up for an average duration of 10.8 years in the longitudinal analysis. Based on serum levels of vitamin D at baseline, participants were categorized into those with severe deficiency (< 25 nmol/L), moderate deficiency (25-49.9 nmol/L), insufficiency (50-74.9 nmol/L), or sufficiency (≥ 75 nmol/L). Cases of cataracts were confirmed from hospital records and self-reported information. TAKEAWAY: Of the 442,255 participants in the cross-sectional analysis, 3.24% had cataracts, and of the 427,923 participants in the longitudinal analysis, 13.02% developed the condition. In cross-sectional analyses, individuals with vitamin D levels < 25 nmol/L had a 12% higher risk for cataracts than those with levels ranging from 50 to 74.9 nmol/L (adjusted hazard ratio [aHR], 1.12; 95% CI, 1.04-1.21). In the longitudinal analysis, participants with vitamin D levels below 25 nmol/L had an 11% higher risk of developing cataracts than those with levels of 50-74.9 nmol/L (aHR, 1.11; 95% CI, 1.07-1.15); the risk was even greater among people younger than 50 years (aHR, 1.27; 95% CI, 1.07-1.49), whereas those aged 60 years or older had a 9% increased risk (aHR, 1.09; 95% CI, 1.04-1.14). IN PRACTICE: 'The study identified significant cross-sectional and prospective associations between vitamin D deficiency and increased cataract risk, with younger individuals being more susceptible,' the researchers reported. 'These findings suggest a potential critical period in early adulthood when vitamin D supplementation may be most effective for cataract prevention, warranting further investigation into age-specific intervention strategies,' they added. SOURCE: This study was led by Yu Peng and Yuzhou Zhang, of the Chinese University of Hong Kong, Hong Kong, China. It was published online on August 18, 2025, in the British Journal of Ophthalmology. LIMITATIONS: Not all cases of cataract may have been identified in this study. This study relied on baseline measurement of vitamin D levels, which did not account for variations during the follow-up period. The findings may not be generalizable to other populations as nearly 95% of participants in the UK Biobank were of White ethnicity. DISCLOSURES: This study was supported partly by the General Research Fund, Research Grants Council, Hong Kong; Collaborative Research Fund; Health and Medical Research Fund, Hong Kong; and other sources. The authors declared no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
5 hours ago
- Yahoo
Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) Approval is based on comprehensive analytical, non-clinical and clinical similarity data, including a confirmatory efficacy study comparing Mynzepli® with the reference biologic Eylea® in patients with neovascular AMD REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited ('Advanz Pharma'), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission has approved Mynzepli® as a biosimilar to Eylea® (aflibercept), in a pre-filled syringe and vial. "Timely access to effective therapies is essential for individuals affected by retinal diseases. With millions of Europeans impacted, the approval of Mynzepli represents important progress in providing innovative and affordable treatment options. This helps to ensure that patients throughout Europe have improved access to vision-preserving care, regardless of financial or logistical barriers," said Joseph McClellan, Chief Scientific and Technical Officer of Alvotech. Nick Warwick, Chief Medical Officer of Advanz Pharma, said 'The approval of Mynzepli® marks an important milestone in our mission to broaden access to high-quality and affordable medicines for patients across Europe.' The centralized marketing authorization is valid in all European Economic Area (EEA) countries, including the 27 member states of the European Union, as well as Norway, Iceland and Lichtenstein. In 2024, global sales of Eylea® were about US$9 billion, and one third of these sales were in Europe [1]. Mynzepli® is approved for all adult indications approved for the reference biologic, neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME) or myopic choroidal neovascularization (myopic CNV). Mynzepli® will be available as a 40 mg/mL solution for injection in a pre-filled syringe and 40 mg/mL solution for injection in a vial. In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with its biosimilar candidate to Eylea®, known as AVT06, comparing the efficacy, safety, and immunogenicity of the proposed biosimilar to Eylea® in patients with neovascular (wet) AMD. The study met its primary endpoint, with results demonstrating therapeutic equivalence between Alvotech's biosimilar candidate and Eylea® [1]. The European Commission's decision to issue a marketing authorization came after the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on approving AVT06, as Mynzepli® (aflibercept). Dossiers for AVT06 are currently under review in multiple countries globally, including the United States and Japan. About Mynzepli® (aflibercept) Mynzepli® (aflibercept) is a recombinant fusion protein which has now been approved in the European Economic Area as a biosimilar to Eylea® (aflibercept). Aflibercept binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability [2]. Sources[1] Agostini, H. (2025). A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 1–15. Product information Use of trademarksElyea® is a registered trademark of Bayer AG. About AlvotechAlvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit None of the information on the Alvotech website shall be deemed part of this press release. About Advanz PharmaAdvanz Pharma is a global pharmaceutical company with the purpose to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Advanz Pharma's headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma's product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Advanz Pharma's products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Advanz Pharma's ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with Advanz Pharma's ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to Advanz Pharma's dedicated and highly qualified employees, acting in line with Advanz Pharma's company values of entrepreneurship, speed, and integrity. Alvotech Forward Looking StatementsCertain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial or operating performance of Alvotech and may include, for example, Alvotech's expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory review and interactions, the timing of the announcement of clinical study results, the commencement of patient studies, regulatory applications, approvals and market launches, and the estimated size of the total addressable market of Alvotech's pipeline products. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to reach development milestones under commercial partnership agreements; (2) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (3) the ability to maintain stock exchange listing; (4) changes in applicable laws or regulations; (5) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (6) Alvotech's estimates of expenses and profitability; (7) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (10) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (11) the ability of Alvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (12) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (13) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (14) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements; (15) Alvotech's ability, and that of its commercial partners to execute their commercialization strategy for approved products; (16) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (17) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (18) the potential impact of the ongoing COVID-19 pandemic on the FDA's review timelines, including its ability to complete timely inspection of manufacturing sites; (19) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Alvotech's business, financial position, strategy and anticipated milestones; and (20) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. Advanz Pharma Forward Looking StatementsCertain statements in this press release are forward-looking statements. These statements may be identified by words such as 'anticipate', "expectation", "belief', "estimate", "plan", "target', 'project', 'will', 'may', 'should' or "forecast" and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma's markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. MEDIA CONTACTSAlvotech Global Communications and Investor RelationsBenedikt Advanz Pharma Global Corporate CommunicationsCourtney in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
